Cardiovascular
Coronary Revascularization
0
Pipeline Programs↗
0
Active Trials↗
1
Companies Involved↗
Coronary Revascularization is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
9
clinical trials
Completed3 · 33%
Unknown status3 · 33%
Withdrawn2 · 22%
Terminated1 · 11%
Clinical Trials
Trial Activity
9 trials
Retinal Microvascular Network and Coronary Revascularization Surgery at the Dijon University Hospital
Completed·—·N/A·NCT05315349·120 enrolled
Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial
Terminated·—·Phase 3·NCT02448550·250 enrolled
Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis
Unknown status·—·Phase 4·NCT02402491·1,000 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)